Still-in-stealth biotech partners with Sloan Kettering scientists to make personalized cancer therapy more ‘public’ – Endpoints News

If the pleasantries exchanged today between the Biogen board and CEO Michel Vounatsos looked a bit intricately scripted to you, even by corporate PR standards, their 10Q filed with the SEC offers a possible glimpse as to why.

It explains just how meticulous they’ve been to avoid any unpleasantries during his long goodbye as the company hunts a successor.

According to a letter filed with the 10Q, the two parties came to an agreement regarding the stock Vounatsos gets next February during their vesting date. Much of the stock will be given on a pro-rated basis now, based on how much time he fulfilled by the time he leaves — rather than lose the shares due to his departure ahead of the vesting date.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 141,100+ biopharma pros reading Endpoints daily — and it’s free.

Give a Comment